RVMD: Revolution Medicines Corp Price to Sales

Corporate company logo of Revolution Medicines Corp (RVMD)

Scaling oncology pipelines requires colossal expenditures, temporarily increasing unit costs. This linear chart of the market price-to-revenue ratio from the GURU.Markets terminal captures current dynamics, where the value has stabilized at 188.70. The absence of sales due to the testing phase zeroes out revenue, eliminating cash flow predictability for Revolution Medicines (RVMD). However, targeted therapy for chronic diseases guarantees multi-year demand for patented solutions.

RevMed - RVMD Price-to-Revenue Ratio (period 07/04/2022 - 11/15/2026)

Revolution Medicines Corp (RVMD) - metric breakdowns and financial figures

Summary company analytics:Revolution Medicines, Inc.
Product sample of RevMed

To qualitatively assess an asset, an investor must compare market capitalization with actual sales volume, which determines the degree of business overvaluation under tight monetary policy. By analyzing the price-to-sales ratio, one can evaluate the resilience of Revolution Medicines (RVMD), whose diversified strategy of developing targeted therapies to combat RAS-dependent tumors minimizes risks by allocating resources across multiple clinical trials.

Competing companies

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Price-to-Revenue Coefficient Ascentage (AAPG)|CGON: Market Cap to Revenue|Price to Sales UroGen Pharma Ltd.|BCAX: P/S Multiple|PSNL - Price-to-Revenue Coefficient|ERAS (Erasca Oncology) - P/S Multiple|P/S Multiple Delcath Systems, Inc.|Price-to-Revenue Ratio ymabs.com (YMAB)|Price-to-Revenue Ratio AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Market Cap to Revenue|Accuray Inc. (ARAY) - Price to Sales|SELLAS Life Sciences Group, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Price-to-Revenue Ratio|HURA - Price-to-Revenue Coefficient|TARA (Protara Therapeutics, Inc.) - P/S Multiple|P/S Multiple Fate Therapeutics Inc|P/S Multiple WHWK|P/S Multiple TScan Therapeutics Inc (TCRX)|Price-to-Revenue Ratio championsoncology.com CSBR|XBIT - Market Cap to Revenue|CVM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OSTX (OS Therapies)|RADX: P/S Multiple|Artiva Biotherapeutics Inc. - Market Capitalization-to-Revenue Ratio|ANL (Adlai Nortye) - P/S Multiple|P/S Multiple verupharma.com|Market Cap to Revenue TPST (tempesttx.com)|Market Cap to Revenue Xilio Therapeutics Inc XLO|P/S Multiple RENB (Enochian BioSciences)|Mural Bio - Price-to-Revenue Ratio|KAPA - Price-to-Revenue Ratio|OnKure Therapeutics (OKUR) - Market Cap to Revenue|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd